Corneal Dystrophy and Netra Restoration Therapy

The Cornea Is More Than a Transparent Window

The cornea is the transparent tissue at the front of the eye. It contributes substantially to the eye's focusing power while also forming a protective barrier against environmental exposure. To remain transparent, the cornea must preserve an unusually precise biological organization. Its epithelial cells must renew themselves while remaining firmly attached to the underlying basement membrane. Stromal collagen fibers must remain uniformly arranged so that light can pass through without excessive scattering. Corneal nerves must provide sensation and trophic signals. Endothelial cells must continuously move excess fluid out of the cornea to prevent swelling.

The cornea does not contain blood vessels within its central transparent region. It receives oxygen and nutrients through the tear film, aqueous humor, limbal circulation, and surrounding tissues. Because it is avascular, claims that corneal dystrophy can be addressed simply by “increasing blood flow to the cornea” would be biologically incomplete.

A more appropriate integrative model considers the entire corneal environment:

• Cellular energy production
• Antioxidant defenses
• Protein quality-control systems
• Extracellular-matrix organization
• Epithelial attachment
• Tear-film stability
• Corneal nerve signaling
• Endothelial pump activity
• Nutrient availability
• Inflammatory regulation
• Systemic metabolic influences
• Exposure to ultraviolet light and other environmental stressors

These systems interact continuously. A disturbance in one pathway may increase stress on several others.

Genetics: The Primary Foundation of Many Corneal Dystrophies

Many corneal dystrophies begin with a pathogenic genetic variant. The affected gene may regulate a structural protein, an enzyme, an ion transporter, a membrane protein, or a component of the extracellular matrix. Variants in TGFBI, for example, are associated with several epithelial-stromal and stromal dystrophies, including granular, lattice, Reis-Bücklers, and Thiel-Behnke corneal dystrophies. Variants in CHST6 interfere with normal keratan-sulfate processing in macular corneal dystrophy. Variants in UBIAD1 are associated with disturbed lipid handling in Schnyder corneal dystrophy. Other corneal dystrophies involve genes such as KRT3, KRT12, SLC4A11, TACSTD2, COL8A2, ZEB1, OVOL2, and TCF4.

A genetic variant may initiate the disease, but genetics alone may not fully explain why severity varies among individuals. Members of the same family who carry a similar genetic change may develop different amounts of corneal haze, recurrent erosion, visual disturbance, or endothelial dysfunction.

This variability suggests that age, environmental exposure, cellular stress responses, protein-clearance capacity, hormonal factors, antioxidant defenses, and other modifying influences may affect how the disease is expressed.

NRT does not modify the responsible gene. Its potential role is limited to supporting the physiological environment in which genetically vulnerable corneal cells must function.

Abnormal Protein Folding and Corneal Deposits

Several corneal dystrophies are disorders of protein production, folding, processing, or removal. The TGFBI gene produces transforming growth factor beta-induced protein, commonly called TGFBIp. This extracellular-matrix protein interacts with collagen, integrins, and other components involved in cellular adhesion and corneal organization.

Certain TGFBI variants alter the stability and behavior of the protein. Instead of remaining properly folded and soluble, altered TGFBIp may become more susceptible to fragmentation, misfolding, aggregation, or deposition within the cornea.

The nature of the deposit differs according to the mutation. Some variants are associated predominantly with amyloid-like deposits, as seen in lattice dystrophy. Others produce non-amyloid granular deposits. In some conditions, the abnormal protein becomes concentrated near Bowman's layer and the superficial stroma.

These deposits interfere with corneal transparency by scattering light. They may also disturb interactions between epithelial cells and the extracellular matrix, alter cellular migration, and contribute to surface instability.

From the NRT perspective, it is essential to separate two different objectives:

• Removing established deposits
• Supporting the cellular environment surrounding those deposits

NRT has not been established as a method of dissolving inherited TGFBI deposits. However, protein aggregation is influenced by the broader cellular environment, including oxidative stress, protein-clearance mechanisms, mitochondrial function, inflammation, and extracellular-matrix turnover.

These secondary pathways provide a biologically relevant area for supportive research, but they should not be described as equivalent to correcting the underlying protein abnormality.

Extracellular-Matrix Disorganization

The corneal extracellular matrix is not simply structural scaffolding. It provides biochemical and mechanical signals that regulate cell attachment, migration, differentiation, survival, and wound repair. Corneal transparency depends on the highly ordered arrangement of stromal collagen and proteoglycans. Abnormal proteins or carbohydrates can disrupt this arrangement, creating irregular spaces, changing stromal hydration, and increasing light scatter.

In macular corneal dystrophy, variants in CHST6 impair the normal sulfation of keratan sulfate. This results in abnormal proteoglycan synthesis and the accumulation of poorly sulfated material within keratocytes and the extracellular matrix. The disturbance is therefore not merely an isolated deposit; it reflects altered carbohydrate metabolism and matrix organization throughout the corneal stroma.

Similar principles apply to other dystrophies. The molecular composition of the deposit, its interaction with collagen, and its effects on cell-matrix communication determine how the disease affects transparency and epithelial stability.

NRT cannot reconstruct severely disorganized stromal architecture. The adjunctive focus is instead placed on factors that support remaining keratocyte function, cellular metabolism, ocular-surface health, and tissue resilience.

Impaired Epithelial Adhesion

In superficial corneal dystrophies, the principal problem may involve the attachment of epithelial cells to the basement membrane. The epithelium is renewed continuously. New epithelial cells must migrate, mature, and anchor securely through specialized structures, including hemidesmosomes and anchoring fibrils. When the basement membrane is irregular, duplicated, thickened, or positioned abnormally, epithelial cells may not attach securely.

Weak adhesion allows portions of the epithelium to separate from the underlying cornea. Repeated epithelial disruption can initiate pain, tearing, light sensitivity, surface inflammation, and fluctuating vision.

Research into recurrent corneal erosion has also implicated abnormal activity of matrix metalloproteinases. These enzymes participate in normal extracellular-matrix remodeling, but excessive or poorly regulated activity may degrade basement-membrane and adhesion-related proteins. This can further weaken epithelial attachment and perpetuate recurrent breakdown.

This pathway is relevant to NRT because epithelial integrity depends on more than lubrication alone. It also requires:

• Healthy basement-membrane organization
• Controlled extracellular-matrix remodeling
• Adequate cellular energy
• Balanced inflammatory signaling
• Normal corneal sensation
• Neurotrophic support
• A stable tear film
• Sufficient epithelial migration and renewal

An integrative program may attempt to support these conditions, but it cannot guarantee that a genetically abnormal basement membrane will become permanently normal.

Oxidative Stress

Oxidative stress develops when the production of reactive oxygen species exceeds the ability of antioxidant and cellular repair systems to control them. The cornea is repeatedly exposed to ultraviolet light, oxygen, environmental pollutants, metabolic activity, and inflammatory mediators. It therefore requires strong antioxidant defenses.

At controlled levels, reactive oxygen species participate in normal cellular signaling. When excessive, they can damage:

• Cellular membranes
• Mitochondrial DNA
• Nuclear DNA
• Structural proteins
• Enzymes
• Lipids
• Extracellular-matrix components

Oxidative injury is particularly relevant to Fuchs endothelial corneal dystrophy. Research has demonstrated reduced antioxidant defense, oxidative DNA damage, mitochondrial abnormalities, and apoptosis within affected corneal endothelial cells. The NRF2 pathway, which regulates several antioxidant and cellular defense genes, has emerged as an important area of investigation in endothelial health.

Oxidative stress may also interact with protein aggregation. Oxidized proteins can become unstable or more difficult for cells to process. Damaged mitochondria can produce additional reactive oxygen species, establishing a self-reinforcing cycle:

Cellular stress → mitochondrial damage → increased reactive oxygen species → protein and DNA injury → further cellular dysfunction

One of the primary biological objectives within NRT is to reduce avoidable oxidative burden and support endogenous antioxidant capacity. This does not mean that antioxidant supplementation alone can reverse corneal dystrophy. Antioxidant strategies must be individualized because excessive, poorly selected, or unmonitored supplementation can be ineffective or inappropriate.

The objective is to support redox balance rather than to treat every form of corneal dystrophy as a simple antioxidant deficiency.

Mitochondrial Dysfunction and Energy Failure

Mitochondria generate much of the energy required for cellular maintenance, ion transport, protein processing, repair, and survival. Corneal endothelial cells are particularly dependent on mitochondrial energy. These cells maintain corneal transparency by operating energy-dependent ion pumps that regulate stromal hydration. They also have limited capacity to divide and replace lost cells.

In Fuchs endothelial corneal dystrophy, studies have identified fragmented mitochondria, impaired mitochondrial membrane potential, abnormal energy metabolism, oxidative mitochondrial DNA damage, reduced mitochondrial mass, and altered mitophagy. These changes can reduce cellular resilience and increase vulnerability to apoptosis.

Mitochondrial health is also important in corneal epithelial cells. Epithelial renewal, migration, adhesion, and wound closure require substantial energy. Experimental evidence indicates that disrupted mitochondrial dynamics can impair corneal epithelial repair and increase DNA damage and cellular stress.

NRT approaches mitochondrial dysfunction as a potential modifiable stress pathway. Depending on the individual, supportive goals may include:

• Reducing excessive oxidative pressure on mitochondria
• Supporting nutritional cofactors required for cellular energy production
• Promoting regular sleep and circadian stability
• Addressing metabolic factors that impair mitochondrial function
• Supporting cellular recovery after repeated epithelial stress
• Considering carefully selected photobiomodulation protocols when clinically appropriate

These strategies remain supportive. They do not replace endothelial cells that have already been lost and do not eliminate the responsible genetic abnormality.

Autophagy, Mitophagy, and Cellular Waste Removal

Cells contain quality-control systems that identify, recycle, or remove damaged proteins and organelles. Autophagy is a process through which cells degrade and recycle damaged cellular components. Mitophagy is the selective removal of damaged mitochondria.

When these systems function properly, they help prevent the accumulation of dysfunctional organelles and potentially toxic proteins. When they are impaired or overwhelmed, abnormal material may persist and contribute to cellular stress.

Altered autophagy and mitophagy have been implicated in several corneal disorders, including Fuchs endothelial corneal dystrophy. Excessive mitochondrial injury can overwhelm mitophagy, while defective clearance can allow damaged mitochondria to remain within the cell and continue generating oxidative stress.

Protein-aggregation dystrophies also raise important questions about proteostasis—the coordinated process through which cells produce, fold, transport, and remove proteins.

A cell may continue producing an abnormal protein for many years. Whether that protein remains soluble, becomes fragmented, forms amyloid, or accumulates as an extracellular deposit may be influenced partly by local proteases, molecular chaperones, autophagy, and other clearance mechanisms.

NRT cannot be described as activating autophagy sufficiently to clear inherited corneal deposits. However, supporting general metabolic health, reducing cellular stress, and avoiding factors that impair normal repair pathways are reasonable adjunctive objectives.

Endoplasmic Reticulum Stress

The endoplasmic reticulum is responsible for folding and processing many proteins before they are transported to other parts of the cell or secreted into the extracellular environment.

When abnormal proteins accumulate within the endoplasmic reticulum, cells activate the unfolded protein response. Initially, this response attempts to restore balance by slowing protein production, increasing protein-folding capacity, and removing defective proteins.

If the stress is prolonged or severe, the unfolded protein response can shift from cellular protection toward apoptosis.

Endoplasmic-reticulum stress has been investigated in Fuchs endothelial corneal dystrophy and in other diseases involving abnormal protein processing. It may interact with mitochondrial dysfunction, oxidative stress, calcium imbalance, and inflammatory signaling.

This illustrates why cellular pathways should not be viewed in isolation. Protein misfolding may produce endoplasmic-reticulum stress. Endoplasmic-reticulum stress may disturb mitochondria. Mitochondrial dysfunction may increase oxidative damage. Oxidative damage may further destabilize proteins.

The NRT framework attempts to identify this network of secondary stress factors rather than claiming that one supplement, herb, or modality addresses the entire disease.

Inflammatory Signaling

Corneal dystrophies have traditionally been classified as non-inflammatory disorders because inflammation is generally not considered the primary initiating cause. However, “not primarily inflammatory” does not mean that inflammatory signaling is biologically irrelevant.

Repeated epithelial breakdown can release damage-associated molecules and stimulate cytokine production. Tear-film instability can activate inflammatory pathways at the ocular surface. Abnormal extracellular-matrix remodeling can involve matrix metalloproteinases. Cellular stress can activate innate immune responses.

In Fuchs endothelial corneal dystrophy, recent studies have identified changes in inflammatory chemokines within the aqueous humor and have suggested broader involvement of inflammatory pathways. These findings do not establish Fuchs dystrophy as a conventional inflammatory disease, but they demonstrate that immune signaling may participate in the stressed endothelial environment.

Inflammation can also amplify oxidative stress. Reactive oxygen species stimulate inflammatory pathways, while activated inflammatory cells and cytokines can generate additional oxidative products.

Within NRT, the objective is not indiscriminate suppression of inflammation. Normal inflammatory signaling is necessary for defense and tissue repair. The objective is to support appropriate resolution and reduce persistent, excessive, or self-perpetuating inflammatory stress when it is present.

This may include attention to:

• Ocular-surface irritation
• Tear-film instability
• Repeated mechanical trauma
• Eye rubbing
• Sleep quality
• Metabolic health
• Dietary patterns
• Environmental exposures
• Systemic inflammatory burden

The clinical relevance of these factors varies considerably between patients.

Ferroptosis and Lipid Peroxidation

Ferroptosis is an iron-dependent form of regulated cell death associated with the accumulation of lipid peroxides within cellular membranes. This pathway differs from conventional apoptosis. It is driven by the interaction of iron, oxidative stress, vulnerable membrane lipids, and insufficient antioxidant defense—particularly inadequate activity of systems that neutralize lipid peroxides.

Ferroptosis has become an important research area in Fuchs endothelial corneal dystrophy. Experimental evidence indicates that the common TCF4 trinucleotide-repeat expansion and ultraviolet exposure may increase the susceptibility of affected endothelial cells to ferroptotic injury. Other studies have explored molecular regulators capable of reducing ferroptosis in experimental Fuchs models.

This pathway is relevant to the established NRT interest in oxidative stress and ferroptosis. However, the evidence remains disease-specific and largely experimental. It would be premature to claim that NRT has been proven to prevent ferroptotic endothelial cell loss in patients with Fuchs dystrophy.

A responsible therapeutic framework may instead consider:

• Oxidative stress regulation
• Antioxidant defense systems
• Iron balance when clinically relevant
• Mitochondrial health
• Lipid-membrane integrity
• Ultraviolet protection
• Avoidance of unnecessary pro-oxidant exposure

Ferroptosis should be presented as a promising biological target for research, not as a clinically proven mechanism of NRT efficacy.

Endothelial Pump Dysfunction and Fluid Imbalance

The endothelial layer consists of a single layer of specialized cells lining the back of the cornea. These cells regulate fluid movement between the aqueous humor and the corneal stroma.

The stroma naturally attracts water because of its proteoglycan composition. Endothelial ion pumps continuously remove excess fluid, keeping the cornea in a relatively dehydrated state required for transparency.

When endothelial cells become dysfunctional or die, the remaining cells enlarge and spread in an attempt to maintain coverage. Eventually, the remaining cells may be unable to sustain adequate pump activity. Fluid then accumulates within the stroma and, later, the epithelium.

This process is metabolically demanding. It connects several pathogenic factors:

• Endothelial cell density
• Mitochondrial ATP production
• Ion-channel activity
• Oxidative damage
• DNA injury
• Extracellular-matrix changes
• Cellular senescence
• Apoptosis or ferroptosis

NRT cannot mechanically restore a severely failed endothelial pump. Adjunctive strategies are most biologically plausible when viable cells remain and the objective is to support metabolic resilience rather than claim cellular replacement.

Corneal Nerves and Neurotrophic Support

The cornea is one of the most densely innervated tissues in the human body. Corneal nerves do more than transmit pain and touch. They release neuropeptides and trophic factors that help regulate epithelial renewal, wound healing, tear production, blinking, and local immune activity. The relationship is bidirectional. Corneal nerves support epithelial cells, while epithelial cells provide signals that support nerve survival.

Repeated epithelial injury may disturb nerve endings and alter sensation. Depending on the pattern of damage and regeneration, a patient may develop reduced sensitivity, exaggerated sensitivity, persistent discomfort, or pain that is disproportionate to visible surface findings.

Corneal nerve health is therefore relevant to patients who experience recurrent erosions, chronic irritation, light sensitivity, or persistent ocular pain.

NRT may consider neurotrophic support through a combination of ocular-surface stabilization, reduction of repeated injury, metabolic support, autonomic regulation, acupuncture, and carefully selected adjunctive modalities.

However, corneal pain must not automatically be attributed to inflammation or structural dystrophy. Nociceptive, neuropathic, and nociplastic mechanisms can overlap. A therapy that improves surface dryness may not adequately address established corneal neuropathic pain.

Tear-Film Instability as a Secondary Amplifier

The tear film creates the eye's first refractive surface. Even when the deeper cornea remains unchanged, an unstable tear film can produce fluctuating vision, glare, ghosting, burning, and reduced visual endurance. Corneal dystrophy can contribute to tear-film instability by creating an irregular epithelial surface. In return, an unstable tear film may increase friction, inflammation, osmotic stress, and epithelial vulnerability.

This creates another cycle:

Surface irregularity → tear-film breakup → increased friction and inflammation → epithelial stress → greater surface irregularity

Addressing the tear film does not remove stromal deposits or correct endothelial dysfunction. It may, however, reduce the portion of a patient's symptoms arising from a modifiable ocular-surface disturbance.

Within NRT, ocular-surface support may include environmental modification, blink rehabilitation, hydration review, eyelid and meibomian-gland support, nutritional assessment, and strategies intended to reduce inflammatory and oxidative stress.

Lipid Metabolism

Not every corneal deposit is composed of protein or abnormal carbohydrate.

Schnyder corneal dystrophy is associated with variants in UBIAD1, a gene involved in lipid and vitamin K-related cellular pathways. Disease-associated UBIAD1 variants may alter enzyme function and intracellular transport, contributing to the accumulation of cholesterol and phospholipid material within the cornea.

This does not mean that Schnyder corneal dystrophy is simply caused by eating too much dietary cholesterol. The primary defect is genetic and involves local cellular handling of lipids.

Nevertheless, lipid metabolism is an example of why corneal dystrophy requires individualized pathogenic analysis. An antioxidant-focused program alone would not fully address abnormal proteoglycan synthesis, epithelial adhesion failure, or genetically altered lipid transport.

NRT must therefore avoid applying the same protocol to every corneal dystrophy.

How Netra Restoration Therapy Is Positioned

Netra Restoration Therapy is an individualized, adjunctive therapeutic framework developed by Netra Eye Institute. For corneal dystrophy, its purpose is to support modifiable physiological pathways surrounding the inherited or structural disorder.

Depending on the patient, NRT may focus on:

• Oxidative-stress regulation
• Mitochondrial and metabolic support
• Ocular-surface stabilization
• Corneal nerve and neurotrophic support
• Inflammatory balance
• Tear-film quality
• Cellular repair capacity
• Nutritional sufficiency
• Ferroptosis-related risk pathways
• Autonomic and stress regulation
• Environmental and lifestyle contributors

The program may incorporate acupuncture, photobiomodulation, nutritional strategies, ocular-surface support, lifestyle modification, and selected principles from traditional East Asian and Ayurvedic medicine.

Each component must have a defined clinical purpose. The inclusion of several modalities does not mean that all are necessary or appropriate for every patient.

What NRT May Realistically Attempt to Improve

The realistic goals of adjunctive care are different from claims of reversing a genetic disorder. Depending on the affected corneal layer and the patient's overall ocular health, supportive objectives may include:

• Improving ocular comfort
• Reducing surface irritation
• Improving tear-film stability
• Supporting epithelial resilience
• Reducing the frequency or intensity of avoidable surface stress
• Supporting corneal nerve function
• Improving visual endurance
• Reducing glare associated with tear-film instability
• Supporting contrast quality when reversible surface factors are present
• Improving sleep, stress regulation, and general treatment adherence
• Reducing modifiable oxidative or inflammatory burden

Any reported improvement must be interpreted carefully. Better comfort or more stable vision does not necessarily mean that stromal deposits have disappeared, endothelial cells have regenerated, or the genetic disease has been reversed.

What NRT Does Not Claim to Do

Netra Restoration Therapy should not be represented as:

• Changing an inherited genetic variant
• Permanently eliminating abnormal protein production
• Dissolving established deep stromal deposits
• Rebuilding severely disorganized corneal collagen
• Replacing lost endothelial cells
• Restoring a failed endothelial pump
• Guaranteeing permanent prevention of epithelial erosion
• Reversing advanced corneal scarring
• Curing every type of corneal dystrophy
• Producing identical results in every patient

These distinctions are essential for informed, ethical care.

An Individualized Pathogenic-Factor Approach

The term “corneal dystrophy” covers disorders with very different mechanisms. A patient with epithelial adhesion failure does not have the same biological problem as a patient with TGFBI protein aggregation, CHST6-related proteoglycan abnormalities, UBIAD1-related lipid deposition, or TCF4-associated endothelial degeneration. For this reason, Netra Eye Institute does not approach corneal dystrophy as a single uniform condition.

The therapeutic reasoning begins by asking:

• Which corneal layer is affected?
• Is the dominant problem epithelial instability, abnormal deposition, stromal disorganization, or endothelial stress?
• Are oxidative and mitochondrial pathways strongly relevant to this type?
• Is ocular-surface disease amplifying the patient's symptoms?
• Are corneal nerve abnormalities contributing to pain or visual intolerance?
• Are there systemic metabolic, nutritional, inflammatory, or environmental stressors?
• Which biological factors are potentially modifiable?
• Which abnormalities are structural and unlikely to respond to supportive therapy?
• What functional outcomes can be monitored responsibly?

This distinction prevents the overuse of generic protocols and helps establish realistic expectations.

Supporting the Physiology Around the Disease

Corneal dystrophy is often defined by what can be seen within the cornea: lines, granules, haze, crystals, abnormal basement membrane, guttae, or swelling. NRT examines the physiology surrounding these visible changes.

It considers whether remaining corneal cells are functioning under excessive oxidative pressure, whether mitochondria have adequate support, whether epithelial attachment is being repeatedly challenged, whether the tear film is unstable, whether inflammatory signaling is perpetuating surface injury, and whether corneal nerves are receiving adequate trophic support.

This does not convert an inherited disease into a lifestyle disorder. Genetics remains central. Structural disease remains structural.

The purpose of a physiological approach is to avoid assuming that nothing modifiable exists simply because the primary disorder is inherited. At the same time, it avoids the opposite error of claiming that modifying secondary pathways can erase the primary genetic defect.

The Netra Eye Institute Perspective

The cornea depends on a coordinated network of proteins, cells, nerves, extracellular matrix, antioxidants, mitochondria, ion pumps, nutrients, and repair mechanisms. A corneal dystrophy may begin with one genetic defect but eventually involve several interacting biological pathways. Netra Restoration Therapy is designed to support the modifiable components of this network. Its potential value lies in improving the physiological environment surrounding viable corneal tissue—not in overstating an ability to reverse every deposit or inherited abnormality.

The potential for improvement varies according to:

• The specific corneal dystrophy
• The layer involved
• The degree of established opacity or swelling
• The number and health of remaining corneal cells
• The presence of recurrent epithelial injury
• Tear-film and eyelid health
• Corneal nerve integrity
• Mitochondrial reserve
• Systemic health
• Environmental exposure
• The presence of other eye disorders

A responsible integrative approach must remain evidence-informed, individualized, measurable, and transparent about its limitations.

Frequently Asked Questions on Corneal Dystrophy

Selected References for Scientific Support

• Weiss JS, Moller HU, Aldave AJ, et al. IC3D Classification of Corneal Dystrophies - Edition 3. Cornea. 2024.
• Moshirfar M, Bennett P, Ronquillo Y. Corneal Dystrophy. StatPearls. Updated 2023.
• EyeWiki. Corneal Stromal Dystrophies. Updated 2026.
• Nanda GG, Alone DP. Current understanding of the pathogenesis of Fuchs endothelial corneal dystrophy. Molecular Vision. 2019.
• Jurkunas UV, et al. Evidence of Oxidative Stress in the Pathogenesis of Fuchs Endothelial Corneal Dystrophy. American Journal of Pathology. 2010.
• Engler C, et al. Unfolded Protein Response in Fuchs Endothelial Corneal Dystrophy. American Journal of Ophthalmology. 2010.
• Kumar V, et al. Mitochondrial Dysfunction and Mitophagy in Fuchs Endothelial Corneal Dystrophy. Cells. 2021.
• Kasi A, et al. Endoplasmic Reticulum-Mitochondria Crosstalk in Fuchs Endothelial Corneal Dystrophy. International Journal of Molecular Sciences. 2025.
• Guha S, et al. SLC4A11 depletion impairs NRF2-mediated antioxidant signaling and increases reactive oxygen species in human corneal endothelial cells during oxidative stress. Scientific Reports. 2017.
• Vallabh NA, Romano V, Willoughby CE. Mitochondrial dysfunction and oxidative stress in corneal disease. Mitochondrion. 2017.
• Sacchetti M, Lambiase A. Neurotrophic factors and corneal nerve regeneration. Neural Regeneration Research. 2017.
• You L, Kruse FE, Volcker HE. Neurotrophic factors in the human cornea. Investigative Ophthalmology & Visual Science. 2000.
• Kahuam-Lopez N, et al. The Role of Nerve Growth Factor on the Ocular Surface. International Journal of Molecular Sciences. 2025.
• Gan X, et al. Network medicine framework reveals generic herb-symptom effectiveness of Traditional Chinese Medicine. arXiv. 2022.
• Bannon ST, et al. MitoQ relieves mitochondrial dysfunction in UVA and cigarette smoke condensate models relevant to Fuchs endothelial corneal dystrophy. Experimental Eye Research. 2024.